Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20340 entries
Sorted by: Best Match Show Resources per page
Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).

Physical biology

Foffi G, Pastore A, Piazza F, Temussi PA.
PMID: 23912807
Phys Biol. 2013 Aug;10(4):040301. doi: 10.1088/1478-3975/10/4/040301. Epub 2013 Aug 02.

More than 60 years of biochemical and biophysical studies have accustomed us to think of proteins as highly purified entities that act in isolation, more or less freely diffusing until they find their cognate partner to bind to. While...

Cite
Foffi G, Pastore A, Piazza F, et al. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012). Phys Biol. 2013;10(4):040301doi: 10.1088/1478-3975/10/4/040301.
Foffi, G., Pastore, A., Piazza, F., & Temussi, P. A. (2013). Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012). Physical biology, 10(4), 040301. https://doi.org/10.1088/1478-3975/10/4/040301
Foffi, G, et al. "Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012)." Physical biology vol. 10,4 (2013): 040301. doi: https://doi.org/10.1088/1478-3975/10/4/040301
Foffi G, Pastore A, Piazza F, Temussi PA. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012). Phys Biol. 2013 Aug;10(4):040301. doi: 10.1088/1478-3975/10/4/040301. Epub 2013 Aug 02. PMID: 23912807.
Copy Download .nbib Format: NLM
Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure.

Circulation. Heart failure

Li C, Zhao M, Xiao L, Wei H, Wen Z, Hu D, Yu B, Sun Y, Gao J, Shen X, Zhang Q, Cao H, Huang J, Huang W, Li K, Huang M, Ni L, Yu T, Ji L, Xu Y, Liu G, Konerman MC, Zheng L, Wen Wang D.
PMID: 34711067
Circ Heart Fail. 2021 Nov;14(11):e008459. doi: 10.1161/CIRCHEARTFAILURE.121.008459. Epub 2021 Oct 29.

BACKGROUND: Cardiac sialylation is involved in a variety of physiological processes in the heart. Altered sialylation has been implicated in heart failure (HF) mice. However, its role in patients with HF is unclear, and the potential effect of modulation...

Cite
Li C, Zhao M, Xiao L, et al. Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure. Circ Heart Fail. 2021;14(11):e008459doi: 10.1161/CIRCHEARTFAILURE.121.008459.
Li, C., Zhao, M., Xiao, L., Wei, H., Wen, Z., Hu, D., Yu, B., Sun, Y., Gao, J., Shen, X., Zhang, Q., Cao, H., Huang, J., Huang, W., Li, K., Huang, M., Ni, L., Yu, T., Ji, L., Xu, Y., Liu, G., Konerman, M. C., Zheng, L., & Wen Wang, D. (2021). Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure. Circulation. Heart failure, 14(11), e008459. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008459
Li, Chenze, et al. "Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure." Circulation. Heart failure vol. 14,11 (2021): e008459. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.121.008459
Li C, Zhao M, Xiao L, Wei H, Wen Z, Hu D, Yu B, Sun Y, Gao J, Shen X, Zhang Q, Cao H, Huang J, Huang W, Li K, Huang M, Ni L, Yu T, Ji L, Xu Y, Liu G, Konerman MC, Zheng L, Wen Wang D. Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure. Circ Heart Fail. 2021 Nov;14(11):e008459. doi: 10.1161/CIRCHEARTFAILURE.121.008459. Epub 2021 Oct 29. PMID: 34711067.
Copy Download .nbib Format: NLM
Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure.

Circulation. Heart failure

Li C, Zhao M, Xiao L, Wei H, Wen Z, Hu D, Yu B, Sun Y, Gao J, Shen X, Zhang Q, Cao H, Huang J, Huang W, Li K, Huang M, Ni L, Yu T, Ji L, Xu Y, Liu G, Konerman MC, Zheng L, Wen Wang D.
PMID: 34711067
Circ Heart Fail. 2021 Nov;14(11):e008459. doi: 10.1161/CIRCHEARTFAILURE.121.008459. Epub 2021 Oct 29.

BACKGROUND: Cardiac sialylation is involved in a variety of physiological processes in the heart. Altered sialylation has been implicated in heart failure (HF) mice. However, its role in patients with HF is unclear, and the potential effect of modulation...

Cite
Li C, Zhao M, Xiao L, et al. Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure. Circ Heart Fail. 2021;14(11):e008459doi: 10.1161/CIRCHEARTFAILURE.121.008459.
Li, C., Zhao, M., Xiao, L., Wei, H., Wen, Z., Hu, D., Yu, B., Sun, Y., Gao, J., Shen, X., Zhang, Q., Cao, H., Huang, J., Huang, W., Li, K., Huang, M., Ni, L., Yu, T., Ji, L., Xu, Y., Liu, G., Konerman, M. C., Zheng, L., & Wen Wang, D. (2021). Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure. Circulation. Heart failure, 14(11), e008459. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008459
Li, Chenze, et al. "Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure." Circulation. Heart failure vol. 14,11 (2021): e008459. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.121.008459
Li C, Zhao M, Xiao L, Wei H, Wen Z, Hu D, Yu B, Sun Y, Gao J, Shen X, Zhang Q, Cao H, Huang J, Huang W, Li K, Huang M, Ni L, Yu T, Ji L, Xu Y, Liu G, Konerman MC, Zheng L, Wen Wang D. Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure. Circ Heart Fail. 2021 Nov;14(11):e008459. doi: 10.1161/CIRCHEARTFAILURE.121.008459. Epub 2021 Oct 29. PMID: 34711067.
Copy Download .nbib Format: NLM
IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus.

Cell reports

Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H.
PMID: 34910942
Cell Rep. 2021 Dec 03;110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03.

Previous studies have shown that the high mortality caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus primarily results from complications of a cytokine storm. Therefore, it is critical to identify the key...

Cite
Yu Y, Xu N, Cheng Q, et al. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021;110126doi: 10.1016/j.celrep.2021.110126.
Yu, Y., Xu, N., Cheng, Q., Deng, F., Liu, M., Zhu, A., Min, Y. Q., Zhu, D., Huang, W., Feng, X., Jing, X., Chen, Y., Yue, D., Fan, Y., Shu, C., Guan, Q., Yang, Z., Zhao, J., Song, W., Guo, D., Liu, H., Zhao, J., Lan, P., Shi, Z., Liu, Y., Chen, X., & Liang, H. (2021). IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell reports, 110126. https://doi.org/10.1016/j.celrep.2021.110126
Yu, Yang, et al. "IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus." Cell reports vol. (2021): 110126. doi: https://doi.org/10.1016/j.celrep.2021.110126
Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021 Dec 03;110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03. PMID: 34910942.
Copy Download .nbib Format: NLM
IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus.

Cell reports

Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H.
PMID: 34910942
Cell Rep. 2021 Dec 03;110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03.

Previous studies have shown that the high mortality caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus primarily results from complications of a cytokine storm. Therefore, it is critical to identify the key...

Cite
Yu Y, Xu N, Cheng Q, et al. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021;110126doi: 10.1016/j.celrep.2021.110126.
Yu, Y., Xu, N., Cheng, Q., Deng, F., Liu, M., Zhu, A., Min, Y. Q., Zhu, D., Huang, W., Feng, X., Jing, X., Chen, Y., Yue, D., Fan, Y., Shu, C., Guan, Q., Yang, Z., Zhao, J., Song, W., Guo, D., Liu, H., Zhao, J., Lan, P., Shi, Z., Liu, Y., Chen, X., & Liang, H. (2021). IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell reports, 110126. https://doi.org/10.1016/j.celrep.2021.110126
Yu, Yang, et al. "IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus." Cell reports vol. (2021): 110126. doi: https://doi.org/10.1016/j.celrep.2021.110126
Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021 Dec 03;110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03. PMID: 34910942; PMCID: PMC8639452.
Copy Download .nbib Format: NLM
IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus.

Cell reports

Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H.
PMID: 34910942
Cell Rep. 2021 Dec 21;37(12):110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03.

Previous studies have shown that the high mortality caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus primarily results from complications of a cytokine storm. Therefore, it is critical to identify the key...

Cite
Yu Y, Xu N, Cheng Q, et al. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021;37(12):110126doi: 10.1016/j.celrep.2021.110126.
Yu, Y., Xu, N., Cheng, Q., Deng, F., Liu, M., Zhu, A., Min, Y. Q., Zhu, D., Huang, W., Feng, X., Jing, X., Chen, Y., Yue, D., Fan, Y., Shu, C., Guan, Q., Yang, Z., Zhao, J., Song, W., Guo, D., Liu, H., Zhao, J., Lan, P., Shi, Z., Liu, Y., Chen, X., & Liang, H. (2021). IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell reports, 37(12), 110126. https://doi.org/10.1016/j.celrep.2021.110126
Yu, Yang, et al. "IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus." Cell reports vol. 37,12 (2021): 110126. doi: https://doi.org/10.1016/j.celrep.2021.110126
Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021 Dec 21;37(12):110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03. PMID: 34910942; PMCID: PMC8639452.
Copy Download .nbib Format: NLM
IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus.

Cell reports

Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H.
PMID: 34910942
Cell Rep. 2021 Dec 21;37(12):110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03.

Previous studies have shown that the high mortality caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus primarily results from complications of a cytokine storm. Therefore, it is critical to identify the key...

Cite
Yu Y, Xu N, Cheng Q, et al. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021;37(12):110126doi: 10.1016/j.celrep.2021.110126.
Yu, Y., Xu, N., Cheng, Q., Deng, F., Liu, M., Zhu, A., Min, Y. Q., Zhu, D., Huang, W., Feng, X., Jing, X., Chen, Y., Yue, D., Fan, Y., Shu, C., Guan, Q., Yang, Z., Zhao, J., Song, W., Guo, D., Liu, H., Zhao, J., Lan, P., Shi, Z., Liu, Y., Chen, X., & Liang, H. (2021). IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell reports, 37(12), 110126. https://doi.org/10.1016/j.celrep.2021.110126
Yu, Yang, et al. "IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus." Cell reports vol. 37,12 (2021): 110126. doi: https://doi.org/10.1016/j.celrep.2021.110126
Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021 Dec 21;37(12):110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03. PMID: 34910942; PMCID: PMC8639452.
Copy Download .nbib Format: NLM
Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.

The Cochrane database of systematic reviews

Sweeney C, Ryan F, Ledwidge M, Ryan C, McDonald K, Watson C, Pharithi RB, Gallagher J.
PMID: 31613983
Cochrane Database Syst Rev. 2019 Oct 15;10:CD013015. doi: 10.1002/14651858.CD013015.pub2. Epub 2019 Oct 15.

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Early intervention for those with high cardiovascular risk is crucial in improving patient outcomes. Traditional prevention strategies for CVD have focused on conventional risk factors, such...

Cite
Sweeney C, Ryan F, Ledwidge M, et al. Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. Cochrane Database Syst Rev. 2019;10:CD013015doi: 10.1002/14651858.CD013015.pub2.
Sweeney, C., Ryan, F., Ledwidge, M., Ryan, C., McDonald, K., Watson, C., Pharithi, R. B., & Gallagher, J. (2019). Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. The Cochrane database of systematic reviews, 10CD013015. https://doi.org/10.1002/14651858.CD013015.pub2
Sweeney, Claire, et al. "Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure." The Cochrane database of systematic reviews vol. 10 (2019): CD013015. doi: https://doi.org/10.1002/14651858.CD013015.pub2
Sweeney C, Ryan F, Ledwidge M, Ryan C, McDonald K, Watson C, Pharithi RB, Gallagher J. Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. Cochrane Database Syst Rev. 2019 Oct 15;10:CD013015. doi: 10.1002/14651858.CD013015.pub2. Epub 2019 Oct 15. PMID: 31613983; PMCID: PMC6953366.
Copy Download .nbib Format: NLM
Asymmetric Conjugate Addition of Azide to alpha,beta-Unsaturated Carbonyl Compounds Catalyzed by Simple Peptides This research was supported by the U.S. National Institutes of Health (GM-57595). We are also grateful to the U.S. National Science Foundation for generous support in the form of a CAREER Award (CHE-9874963). In addition, we thank DuPont, Eli Lilly, Glaxo-Wellcome, and the Merck Chemistry Council for research support. S.J.M. is a Fellow of the Alfred P. Sloan Foundation, a Cottrell Sc.

Angewandte Chemie (International ed. in English)

Horstmann TE, Guerin DJ, Miller SJ.
PMID: 11091422
Angew Chem Int Ed Engl. 2000 Oct 16;39(20):3635-3638. doi: 10.1002/1521-3773(20001016)39:20<3635::aid-anie3635>3.0.co;2-y.

No abstract available.

Cite
Horstmann TE, Guerin DJ, Miller SJ. Asymmetric Conjugate Addition of Azide to alpha,beta-Unsaturated Carbonyl Compounds Catalyzed by Simple Peptides This research was supported by the U.S. National Institutes of Health (GM-57595). We are also grateful to the U.S. National Science Foundation for generous support in the form of a CAREER Award (CHE-9874963). In addition, we thank DuPont, Eli Lilly, Glaxo-Wellcome, and the Merck Chemistry Council for research support. S.J.M. is a Fellow of the Alfred P. Sloan Foundation, a Cottrell Sc. Angew Chem Int Ed Engl. 2000;39(20):3635-3638doi: 10.1002/1521-3773(20001016)39:20<3635::aid-anie3635>3.0.co;2-y.
Horstmann, T. E., Guerin, D. J., & Miller, S. J. (2000). Asymmetric Conjugate Addition of Azide to alpha,beta-Unsaturated Carbonyl Compounds Catalyzed by Simple Peptides This research was supported by the U.S. National Institutes of Health (GM-57595). We are also grateful to the U.S. National Science Foundation for generous support in the form of a CAREER Award (CHE-9874963). In addition, we thank DuPont, Eli Lilly, Glaxo-Wellcome, and the Merck Chemistry Council for research support. S.J.M. is a Fellow of the Alfred P. Sloan Foundation, a Cottrell Sc. Angewandte Chemie (International ed. in English), 39(20), 3635-3638. https://doi.org/10.1002/1521-3773(20001016)39:20<3635::aid-anie3635>3.0.co;2-y
Horstmann, et al. "Asymmetric Conjugate Addition of Azide to alpha,beta-Unsaturated Carbonyl Compounds Catalyzed by Simple Peptides This research was supported by the U.S. National Institutes of Health (GM-57595). We are also grateful to the U.S. National Science Foundation for generous support in the form of a CAREER Award (CHE-9874963). In addition, we thank DuPont, Eli Lilly, Glaxo-Wellcome, and the Merck Chemistry Council for research support. S.J.M. is a Fellow of the Alfred P. Sloan Foundation, a Cottrell Sc." Angewandte Chemie (International ed. in English) vol. 39,20 (2000): 3635-3638. doi: https://doi.org/10.1002/1521-3773(20001016)39:20<3635::aid-anie3635>3.0.co;2-y
Horstmann TE, Guerin DJ, Miller SJ. Asymmetric Conjugate Addition of Azide to alpha,beta-Unsaturated Carbonyl Compounds Catalyzed by Simple Peptides This research was supported by the U.S. National Institutes of Health (GM-57595). We are also grateful to the U.S. National Science Foundation for generous support in the form of a CAREER Award (CHE-9874963). In addition, we thank DuPont, Eli Lilly, Glaxo-Wellcome, and the Merck Chemistry Council for research support. S.J.M. is a Fellow of the Alfred P. Sloan Foundation, a Cottrell Sc. Angew Chem Int Ed Engl. 2000 Oct 16;39(20):3635-3638. doi: 10.1002/1521-3773(20001016)39:20<3635::aid-anie3635>3.0.co;2-y. PMID: 11091422.
Copy Download .nbib Format: NLM
Elevated lipoprotein(a) and lipoprotein-associated phospholipase A.

Journal of neuroinflammation

Jiang X, Xu J, Hao X, Xue J, Li K, Jin A, Lin J, Meng X, Zheng L, Wang Y.
PMID: 34963487
J Neuroinflammation. 2021 Dec 28;18(1):307. doi: 10.1186/s12974-021-02359-w.

BACKGROUND: The association of lipoprotein(a) [Lp(a)] and stroke functional outcomes was conflicting. The aim of the study was to clarify whether high Lp(a) is associated with unfavorable functional outcomes in patients with ischemic stroke.METHODS: A total of 9709 individuals...

Cite
Jiang X, Xu J, Hao X, et al. Elevated lipoprotein(a) and lipoprotein-associated phospholipase A. J Neuroinflammation. 2021;18(1):307doi: 10.1186/s12974-021-02359-w.
Jiang, X., Xu, J., Hao, X., Xue, J., Li, K., Jin, A., Lin, J., Meng, X., Zheng, L., & Wang, Y. (2021). Elevated lipoprotein(a) and lipoprotein-associated phospholipase A. Journal of neuroinflammation, 18(1), 307. https://doi.org/10.1186/s12974-021-02359-w
Jiang, Xue, et al. "Elevated lipoprotein(a) and lipoprotein-associated phospholipase A." Journal of neuroinflammation vol. 18,1 (2021): 307. doi: https://doi.org/10.1186/s12974-021-02359-w
Jiang X, Xu J, Hao X, Xue J, Li K, Jin A, Lin J, Meng X, Zheng L, Wang Y. Elevated lipoprotein(a) and lipoprotein-associated phospholipase A. J Neuroinflammation. 2021 Dec 28;18(1):307. doi: 10.1186/s12974-021-02359-w. PMID: 34963487.
Copy Download .nbib Format: NLM
Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]
PMID: 23074399
Ont Health Technol Assess Ser. 2010;10(21):1-111. Epub 2010 Dec 01.

LITERATURE SEARCH: A literature search was performed on November 13(th), 2009 using OVID MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, the Cumulative Index to Nursing & Allied Health Literature (CINAHL), the Cochrane Library, and the International Agency for...

Cite
Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(21):1-111
(2010). Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis. Ontario health technology assessment series, 10(21), 1-111.
"Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis." Ontario health technology assessment series vol. 10,21 (2010): 1-111.
Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(21):1-111. Epub 2010 Dec 01. PMID: 23074399; PMCID: PMC3377499.
Copy Download .nbib Format: NLM
Elevated lipoprotein(a) and lipoprotein-associated phospholipase A.

Journal of neuroinflammation

Jiang X, Xu J, Hao X, Xue J, Li K, Jin A, Lin J, Meng X, Zheng L, Wang Y.
PMID: 34963487
J Neuroinflammation. 2021 Dec 28;18(1):307. doi: 10.1186/s12974-021-02359-w.

BACKGROUND: The association of lipoprotein(a) [Lp(a)] and stroke functional outcomes was conflicting. The aim of the study was to clarify whether high Lp(a) is associated with unfavorable functional outcomes in patients with ischemic stroke.METHODS: A total of 9709 individuals...

Cite
Jiang X, Xu J, Hao X, et al. Elevated lipoprotein(a) and lipoprotein-associated phospholipase A. J Neuroinflammation. 2021;18(1):307doi: 10.1186/s12974-021-02359-w.
Jiang, X., Xu, J., Hao, X., Xue, J., Li, K., Jin, A., Lin, J., Meng, X., Zheng, L., & Wang, Y. (2021). Elevated lipoprotein(a) and lipoprotein-associated phospholipase A. Journal of neuroinflammation, 18(1), 307. https://doi.org/10.1186/s12974-021-02359-w
Jiang, Xue, et al. "Elevated lipoprotein(a) and lipoprotein-associated phospholipase A." Journal of neuroinflammation vol. 18,1 (2021): 307. doi: https://doi.org/10.1186/s12974-021-02359-w
Jiang X, Xu J, Hao X, Xue J, Li K, Jin A, Lin J, Meng X, Zheng L, Wang Y. Elevated lipoprotein(a) and lipoprotein-associated phospholipase A. J Neuroinflammation. 2021 Dec 28;18(1):307. doi: 10.1186/s12974-021-02359-w. PMID: 34963487; PMCID: PMC8715597.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20340 entries